Ultragenyx_GTX-102-CL301

What is the Purpose of this Study?

GTX-102 is a human ubiquitin-protein ligase E3A antisense (UBE3A-AS) transcript-targeted antisense oligonucleotide (ASO) intended for the treatment of Angelman syndrome (AS). Findings from the Phase 1/2 dose-finding study (GTX-102-001) suggest a positive efficacy signal and favorable benefit risk profile for GTX-102 in pediatric patients with AS. The purpose of this study is to investigate the efficacy and safety of GTX-102 in AS.


Eligibility

  • * Signed informed consent from parent(s) or legal guardian(s)
  • * Confirmed diagnosis of AS with genetic confirmation of full maternal ubiquitin-protein ligase E3A (UBE3A) gene deletion causing AS in the region of 15q11.2 q13
  • * Able to ambulate independently, or with assistance at the Screening Visit (note, a child whose primary means of mobility is by wheelchair is excluded from the study)
  • * Platelet count, prothrombin time / international normalized ratio, and partial thromboplastin time within 1.5x the normal limits at the Screening Visit
Show more

Where can I participate?

Beverly

More about this Clinical Trial

What is the full name of this clinical trial?

A Phase 3, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome

Study Details
Disease Type/Condition

Other

Principal Investigator

Ochoa-Lubinoff, Cesar

Co-Investigators

Jeffrey Swarz, Michelle Allen-Sharpley

Age Group

Children

Phase

III

IRB Number

STUDY00003774

ClinicalTrials.gov ID

NCT06617429

Key Eligibility
ClinicalTrials.gov

How do I learn more about this study?
Email
clinicaltrials@cshs.org
Study Detail
Disease Type/Condition

Other

Principal Investigator

Ochoa-Lubinoff, Cesar

Age Group

Children

Phase

III

IRB Number

GTX-102-CL301

ClinicalTrials.gov ID

NCT06617429

Key Eligibility
ClinicalTrials.gov

Contact
Email
clinicaltrials@cshs.org